

## **New Clinical Data For Covalon's ColActive® Line Of Patented Advanced Wound Care Products To Be Presented At Sawc Spring**

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Apr. 26, 2018-- Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced that two clinical case studies demonstrating the clinical effectiveness of ColActive® Plus and ColActive® Transfer biological matrix products will be presented at the 2018 Symposium on Advanced Wound Care Spring ("SAWC Spring") in Charlotte, North Carolina. In addition to the posters, Covalon will also be showcasing its full line of advanced wound care dressings in the symposium's exhibition hall during the three-day event.

"We are very pleased with the results of these two clinical case studies and believe that they show the advantage that the patented ColActive technology can add to a wound care clinician's arsenal," said Brian Pedlar, Chief Executive Office of Covalon.

Dr. Jeffrey Lehrman, DPM, FASPS, MAPWCA will present a clinical poster entitled *A New Approach in the Management of Chronic Diabetic Foot Ulcers: A Report on the Use of a Collagen Wound Contact Layer with Negative Pressure Wound Therapy* during the SAWC Spring - WHS Poster Gala, held on Friday, April 27th from 7:15 p.m. to 8:45 p.m.

"The combination of a collagen wound contact layer and weekly negative pressure wound therapy had a significant beneficial effect on healing in this chronic diabetic foot ulcer," said Dr. Lehrman. "The regimen was well tolerated and simple to administer and offers a valuable opportunity for healing in this patient group."

Also being presented at the SAWC Spring - WHS Poster Gala is a clinical case series entitled *A New Approach in the Treatment of Chronic Pressure Ulcers at our Center: A Report on the Use of Collagen in Saudi Arabia* by Abdulkareem Iblasi, RN, MSN, and Manju Paulose of King Saud Medical City in Riyadh, Saudi Arabia.

SAWC is the Official Meeting for Members of The Association for the Advancement of Wound Care and the leading national wound healing conference SAWC Spring serves as a forum to connect the entire wound care team — physicians, nurses, physical therapists, researchers, scientists, podiatrists, and dietitians — with the foremost experts in wound care to improve patient outcomes through education. No other wound care conference offers the level of education, advanced state-of-the-art clinical reviews and emerging research findings. The conference runs from April 26-28, 2017, and Covalon will be exhibiting in booth #1311 during all exhibit hours throughout the meeting.

Covalon offers unique, patent protected infection management and advanced wound management solutions for the wound clinician. Covalon's CovaWound™ and ColActive® brands when used together have the ability to rapidly promote wound closure and healing in both acute and chronic wounds.

### **About Covalon**

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at [www.covalon.com](http://www.covalon.com)

*Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.*

*This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan", "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.*

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180426006036/en/>

Source: Covalon Technologies Ltd.

Covalon Technologies Ltd.

Brian Pedlar, 905-568-8400 x 233

CEO

[bpedlar@covalon.com](mailto:bpedlar@covalon.com)

Toll free: 1-877-711-6055

Web site: [www.covalon.com](http://www.covalon.com)

Twitter: @covalon

---

<https://ir.covalon.com/press-releases?item=137>